|
1
|
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.
|
Int J Radiat Oncol Biol Phys
|
2007
|
3.65
|
|
2
|
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
|
Hepatology
|
2008
|
3.52
|
|
3
|
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
|
J Clin Oncol
|
2009
|
3.43
|
|
4
|
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
|
J Natl Compr Canc Netw
|
2009
|
3.25
|
|
5
|
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.
|
Hepatology
|
2014
|
2.14
|
|
6
|
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
|
JAMA
|
2010
|
1.84
|
|
7
|
Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
|
Am J Clin Oncol
|
2008
|
1.84
|
|
8
|
Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.
|
Radiology
|
2014
|
1.78
|
|
9
|
Radioembolization with 90Y microspheres: angiographic and technical considerations.
|
Cardiovasc Intervent Radiol
|
2007
|
1.73
|
|
10
|
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.
|
J Surg Oncol
|
2006
|
1.68
|
|
11
|
Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.
|
Cardiovasc Intervent Radiol
|
2006
|
1.64
|
|
12
|
Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.
|
AJR Am J Roentgenol
|
2011
|
1.64
|
|
13
|
Transcatheter intraarterial therapies: rationale and overview.
|
Radiology
|
2011
|
1.59
|
|
14
|
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
|
J Vasc Interv Radiol
|
2005
|
1.58
|
|
15
|
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.
|
Gastroenterology
|
2004
|
1.57
|
|
16
|
Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.
|
Radiology
|
2010
|
1.55
|
|
17
|
Complications of renal transplantation.
|
Radiographics
|
2005
|
1.55
|
|
18
|
Angiographic considerations in patients undergoing liver-directed therapy.
|
J Vasc Interv Radiol
|
2005
|
1.54
|
|
19
|
Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET.
|
AJR Am J Roentgenol
|
2007
|
1.51
|
|
20
|
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.51
|
|
21
|
Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
|
J Vasc Interv Radiol
|
2013
|
1.47
|
|
22
|
Optional or permanent: clinical factors that optimize inferior vena cava filter utilization.
|
J Vasc Interv Radiol
|
2012
|
1.46
|
|
23
|
Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic.
|
J Vasc Interv Radiol
|
2010
|
1.46
|
|
24
|
Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.
|
AJR Am J Roentgenol
|
2007
|
1.45
|
|
25
|
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
|
Radiology
|
2008
|
1.45
|
|
26
|
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.
|
Hepatology
|
2009
|
1.44
|
|
27
|
Primary failure of uterine artery embolization: use of magnetic resonance imaging to select patients for repeated embolization.
|
J Vasc Interv Radiol
|
2005
|
1.43
|
|
28
|
Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.
|
J Vasc Interv Radiol
|
2009
|
1.43
|
|
29
|
Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies.
|
Med Phys
|
2011
|
1.42
|
|
30
|
Sustained safety and efficacy of extended-shelf-life (90)Y glass microspheres: long-term follow-up in a 134-patient cohort.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.42
|
|
31
|
Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
|
J Vasc Interv Radiol
|
2013
|
1.41
|
|
32
|
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.
|
J Vasc Interv Radiol
|
2005
|
1.39
|
|
33
|
Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy.
|
J Vasc Interv Radiol
|
2007
|
1.39
|
|
34
|
Biliary sequelae following radioembolization with Yttrium-90 microspheres.
|
J Vasc Interv Radiol
|
2008
|
1.33
|
|
35
|
Liver tumors: monitoring embolization in rabbits with VX2 tumors--transcatheter intraarterial first-pass perfusion MR imaging.
|
Radiology
|
2007
|
1.32
|
|
36
|
Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept.
|
J Nucl Med
|
2010
|
1.30
|
|
37
|
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
|
Ann Surg
|
2008
|
1.30
|
|
38
|
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
|
HPB (Oxford)
|
2010
|
1.30
|
|
39
|
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.
|
World J Gastroenterol
|
2008
|
1.30
|
|
40
|
Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs.
|
J Vasc Interv Radiol
|
2008
|
1.29
|
|
41
|
Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.
|
J Vasc Interv Radiol
|
2012
|
1.25
|
|
42
|
Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
|
Eur J Nucl Med Mol Imaging
|
2002
|
1.25
|
|
43
|
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.
|
J Hepatol
|
2010
|
1.25
|
|
44
|
Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay.
|
Radiographics
|
2008
|
1.25
|
|
45
|
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.
|
Gastroenterology
|
2011
|
1.25
|
|
46
|
A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring.
|
J Vasc Interv Radiol
|
2007
|
1.23
|
|
47
|
Effect of C-arm angiographic CT on transcatheter arterial chemoembolization of liver tumors.
|
J Vasc Interv Radiol
|
2007
|
1.20
|
|
48
|
Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors.
|
J Vasc Interv Radiol
|
2008
|
1.19
|
|
49
|
Transcatheter intraarterial perfusion: MR monitoring of chemoembolization for hepatocellular carcinoma--feasibility of initial clinical translation.
|
Radiology
|
2008
|
1.19
|
|
50
|
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.
|
J Natl Compr Canc Netw
|
2009
|
1.19
|
|
51
|
Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.
|
Cancer
|
2009
|
1.19
|
|
52
|
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.
|
Cardiovasc Intervent Radiol
|
2009
|
1.18
|
|
53
|
Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.
|
Ann Surg Oncol
|
2009
|
1.17
|
|
54
|
Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.
|
J Vasc Interv Radiol
|
2007
|
1.16
|
|
55
|
Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.
|
J Vasc Interv Radiol
|
2009
|
1.16
|
|
56
|
Multishot diffusion-weighted PROPELLER magnetic resonance imaging of the abdomen.
|
Invest Radiol
|
2006
|
1.15
|
|
57
|
Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study.
|
Cancer
|
2008
|
1.14
|
|
58
|
Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
|
Radiographics
|
2011
|
1.11
|
|
59
|
MR tracking of iron-labeled glass radioembolization microspheres during transcatheter delivery to rabbit VX2 liver tumors: feasibility study.
|
Radiology
|
2008
|
1.11
|
|
60
|
Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.10
|
|
61
|
Assessment of liver tumor response to therapy: role of quantitative imaging.
|
Radiographics
|
2013
|
1.10
|
|
62
|
Comparison of transcatheter intraarterial perfusion MR imaging and fluorescent microsphere perfusion measurements during transcatheter arterial embolization of rabbit liver tumors.
|
J Vasc Interv Radiol
|
2007
|
1.10
|
|
63
|
Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
|
Cancer J
|
2010
|
1.09
|
|
64
|
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
|
J Hepatol
|
2013
|
1.08
|
|
65
|
Radioembolization for the treatment of liver tumors general principles.
|
Am J Clin Oncol
|
2012
|
1.07
|
|
66
|
Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors.
|
J Vasc Interv Radiol
|
2007
|
1.07
|
|
67
|
The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases.
|
J Vasc Interv Radiol
|
2009
|
1.06
|
|
68
|
In regard to Yu et al.
|
Int J Radiat Oncol Biol Phys
|
2013
|
1.06
|
|
69
|
Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations.
|
Am J Clin Oncol
|
2011
|
1.06
|
|
70
|
Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.
|
J Hepatol
|
2012
|
1.06
|
|
71
|
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.
|
Ann Surg Oncol
|
2013
|
1.05
|
|
72
|
Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
|
J Vasc Interv Radiol
|
2008
|
1.03
|
|
73
|
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
|
J Vasc Interv Radiol
|
2007
|
1.02
|
|
74
|
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.01
|
|
75
|
Comparison between intravenous and intraarterial contrast injections for dynamic 3D MRI of liver tumors in the VX2 rabbit model.
|
J Magn Reson Imaging
|
2006
|
1.01
|
|
76
|
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
|
J Vasc Interv Radiol
|
2005
|
1.01
|
|
77
|
In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla.
|
Invest Radiol
|
2006
|
1.00
|
|
78
|
Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results.
|
J Vasc Interv Radiol
|
2008
|
1.00
|
|
79
|
Venous thromboembolic disease. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.98
|
|
80
|
Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival.
|
J Vasc Interv Radiol
|
2009
|
0.98
|
|
81
|
Radiologic findings following Y90 radioembolization for primary liver malignancies.
|
Abdom Imaging
|
2009
|
0.97
|
|
82
|
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
|
J Hepatol
|
2012
|
0.96
|
|
83
|
Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report.
|
Am J Clin Oncol
|
2012
|
0.96
|
|
84
|
Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization.
|
J Vasc Interv Radiol
|
2006
|
0.96
|
|
85
|
Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.
|
World J Gastroenterol
|
2010
|
0.95
|
|
86
|
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
|
Hepatology
|
2013
|
0.95
|
|
87
|
Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report.
|
Liver Transpl
|
2005
|
0.95
|
|
88
|
Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma.
|
J Magn Reson Imaging
|
2010
|
0.94
|
|
89
|
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
|
J Vasc Interv Radiol
|
2013
|
0.93
|
|
90
|
General selection criteria of patients for radioembolization of liver tumors: an international working group report.
|
Am J Clin Oncol
|
2011
|
0.92
|
|
91
|
Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy.
|
Eur J Nucl Med Mol Imaging
|
2014
|
0.91
|
|
92
|
Radioembolization with 90Y microspheres: technical considerations.
|
J Vasc Interv Radiol
|
2007
|
0.91
|
|
93
|
Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.
|
Hepatology
|
2012
|
0.91
|
|
94
|
The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
|
J Vasc Interv Radiol
|
2005
|
0.91
|
|
95
|
MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques.
|
Acad Radiol
|
2011
|
0.91
|
|
96
|
Thoracic duct embolization: a new treatment for massive leak after neck dissection.
|
Laryngoscope
|
2008
|
0.91
|
|
97
|
Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization.
|
J Vasc Interv Radiol
|
2008
|
0.90
|
|
98
|
90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.
|
J Vasc Interv Radiol
|
2007
|
0.89
|
|
99
|
Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.
|
AJR Am J Roentgenol
|
2011
|
0.89
|
|
100
|
Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.
|
Eur J Cancer
|
2013
|
0.88
|
|
101
|
Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.
|
Semin Intervent Radiol
|
2006
|
0.88
|
|
102
|
Fibrin cap disruption: an adjunctive technique for inferior vena cava filter retrieval.
|
J Vasc Interv Radiol
|
2012
|
0.88
|
|
103
|
Hepatic radioembolization complicated by gastrointestinal ulceration.
|
Semin Intervent Radiol
|
2011
|
0.88
|
|
104
|
Emerging approaches in hepatocellular carcinoma.
|
J Clin Gastroenterol
|
2007
|
0.88
|
|
105
|
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis.
|
Cardiovasc Intervent Radiol
|
2009
|
0.88
|
|
106
|
MR imaging perfusion mismatch: a technique to verify successful targeting of liver tumors during transcatheter arterial chemoembolization.
|
J Vasc Interv Radiol
|
2008
|
0.87
|
|
107
|
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2008
|
0.87
|
|
108
|
Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization.
|
J Vasc Interv Radiol
|
2010
|
0.87
|
|
109
|
Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors.
|
ACS Nano
|
2013
|
0.87
|
|
110
|
Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation.
|
J Gastrointest Surg
|
2006
|
0.86
|
|
111
|
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.86
|
|
112
|
Optimizing IVC filter utilization: a prospective study of the impact of interventional radiologist consultation.
|
J Am Coll Radiol
|
2012
|
0.86
|
|
113
|
Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization.
|
J Vasc Interv Radiol
|
2007
|
0.86
|
|
114
|
Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
|
J Nucl Med
|
2004
|
0.86
|
|
115
|
Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review.
|
J Vasc Interv Radiol
|
2012
|
0.86
|
|
116
|
Radioembolization of renal cell carcinoma using yttrium-90 microspheres.
|
J Vasc Interv Radiol
|
2013
|
0.86
|
|
117
|
Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
|
HPB (Oxford)
|
2014
|
0.85
|
|
118
|
Imaging characteristics following 90yttrium microsphere treatment for unresectable liver cancer.
|
J Med Imaging Radiat Oncol
|
2011
|
0.85
|
|
119
|
Radiologically guided percutaneous fine-needle aspiration biopsy of the liver: retrospective study of 119 cases evaluating diagnostic effectiveness and clinical complications.
|
Diagn Cytopathol
|
2002
|
0.85
|
|
120
|
Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
|
Cancer Biother Radiopharm
|
2010
|
0.85
|
|
121
|
Feasibility of blood oxygenation level-dependent MR imaging to monitor hepatic transcatheter arterial embolization in rabbits.
|
J Vasc Interv Radiol
|
2005
|
0.85
|
|
122
|
Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres.
|
J Vasc Interv Radiol
|
2013
|
0.84
|
|
123
|
Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
|
J Vasc Interv Radiol
|
2005
|
0.84
|
|
124
|
Determination of optimal gadolinium concentration using SSFP for catheter-directed contrast-enhanced coronary MR angiography.
|
Acad Radiol
|
2005
|
0.84
|
|
125
|
Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers.
|
Am J Clin Oncol
|
2012
|
0.84
|
|
126
|
Development of a VX2 pancreatic cancer model in rabbits: a pilot study.
|
J Vasc Interv Radiol
|
2009
|
0.84
|
|
127
|
Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
|
Cancer
|
2012
|
0.84
|
|
128
|
Radioembolization of yttrium-90 microspheres for hepatic malignancy.
|
Semin Intervent Radiol
|
2008
|
0.83
|
|
129
|
Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
|
Recent Results Cancer Res
|
2013
|
0.83
|
|
130
|
Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.
|
Cancer Biother Radiopharm
|
2006
|
0.83
|
|
131
|
Yttrium-90 radioembolization is a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases: further evidence in support of a new treatment paradigm.
|
Ann Surg Oncol
|
2014
|
0.82
|
|
132
|
Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI.
|
Eur Radiol
|
2015
|
0.82
|
|
133
|
Quantitative 4D transcatheter intraarterial perfusion MRI for standardizing angiographic chemoembolization endpoints.
|
AJR Am J Roentgenol
|
2011
|
0.82
|
|
134
|
Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments.
|
J Hepatol
|
2013
|
0.82
|
|
135
|
Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study.
|
J Vasc Interv Radiol
|
2009
|
0.82
|
|
136
|
Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver.
|
Am J Clin Oncol
|
2012
|
0.82
|
|
137
|
Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma.
|
Acad Radiol
|
2011
|
0.81
|
|
138
|
Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases.
|
Am J Clin Oncol
|
2012
|
0.81
|
|
139
|
Yttrium-90 radioembolization in the management of liver malignancies.
|
Semin Oncol
|
2010
|
0.80
|
|
140
|
Cancer concepts and principles: primer for the interventional oncologist-part II.
|
J Vasc Interv Radiol
|
2013
|
0.80
|
|
141
|
Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization.
|
Cardiovasc Intervent Radiol
|
2011
|
0.80
|
|
142
|
Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.
|
Curr Treat Options Oncol
|
2012
|
0.80
|
|
143
|
Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET?
|
Radiology
|
2010
|
0.80
|
|
144
|
Radioembolization for primary and metastatic liver cancer.
|
Semin Radiat Oncol
|
2011
|
0.80
|
|
145
|
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?
|
J Clin Oncol
|
2012
|
0.80
|
|
146
|
Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
|
J Vasc Interv Radiol
|
2013
|
0.80
|
|
147
|
A simple fluoroscopic approach to percutaneous transgastric cystgastrostomy with internalized drainage catheter for treatment of pancreatic pseudocysts: report of two cases.
|
Dig Dis Sci
|
2009
|
0.79
|
|
148
|
Seven-tesla magnetic resonance imaging accurately quantifies intratumoral uptake of therapeutic nanoparticles in the McA rat model of hepatocellular carcinoma: preclinical study in a rodent model.
|
Invest Radiol
|
2014
|
0.79
|
|
149
|
Locoregional chemoembolic delivery: prediction with transcatheter intraarterial perfusion MRI.
|
AJR Am J Roentgenol
|
2012
|
0.79
|
|
150
|
Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction.
|
J Vasc Interv Radiol
|
2010
|
0.79
|
|
151
|
Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.
|
Future Oncol
|
2007
|
0.79
|
|
152
|
Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease.
|
Am J Clin Oncol
|
2009
|
0.78
|
|
153
|
Transjugular intrahepatic portosystemic shunt with thrombectomy for the treatment of portal vein thrombosis after liver transplantation.
|
Dig Dis Sci
|
2009
|
0.78
|
|
154
|
Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments.
|
Cardiovasc Intervent Radiol
|
2008
|
0.78
|
|
155
|
Imaging tumor response following liver-directed intra-arterial therapy.
|
Abdom Imaging
|
2013
|
0.78
|
|
156
|
Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
|
Abdom Imaging
|
2015
|
0.78
|
|
157
|
Minimally invasive therapies for hepatic malignancy.
|
Curr Probl Surg
|
2013
|
0.77
|
|
158
|
Cancer concepts and principles: primer for the interventional oncologist-part I.
|
J Vasc Interv Radiol
|
2013
|
0.77
|
|
159
|
Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma.
|
Radiology
|
2014
|
0.77
|
|
160
|
Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.77
|
|
161
|
New Developments in Interventional Oncology: Liver Metastases From Colorectal Cancer.
|
Cancer J
|
2016
|
0.77
|
|
162
|
Functional magnetic resonance imaging in an animal model of pancreatic cancer.
|
World J Gastroenterol
|
2010
|
0.76
|
|
163
|
Hepatic radioembolization complicated by abscess.
|
Semin Intervent Radiol
|
2011
|
0.76
|
|
164
|
Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
|
Melanoma Res
|
2014
|
0.76
|
|
165
|
Four-dimensional transcatheter intraarterial perfusion MRI monitoring of radiofrequency ablation of rabbit VX2 liver tumors.
|
J Magn Reson Imaging
|
2011
|
0.75
|
|
166
|
Positron emission tomography/CT after yttrium-90 radioembolization: current and future applications.
|
J Vasc Interv Radiol
|
2013
|
0.75
|
|
167
|
Invited commentary.
|
J Vasc Interv Radiol
|
2011
|
0.75
|
|
168
|
Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement.
|
HPB (Oxford)
|
2013
|
0.75
|
|
169
|
Closure of a ureterocutaneous fistula with a covered stent-graft.
|
J Vasc Interv Radiol
|
2003
|
0.75
|
|
170
|
Direct hepatic artery puncture for transarterial therapy in liver cancer.
|
J Vasc Interv Radiol
|
2010
|
0.75
|
|
171
|
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
|
Pancreas
|
2017
|
0.75
|
|
172
|
Locoregional Therapies for Primary and Secondary Hepatic Malignancies.
|
Cancer Treat Res
|
1
|
0.75
|